In another study, samples were retrospectively grouped according to ATRX, IDH and 1p/19q status, where astrocytomas with ATRX loss revealed a significantly better prognosis than those with ATRX retention (median time to treatment failure 55.6 vs. 31.8 months) [11]. Here, ATRX is linked to astrocytoma (excluding glioblastoma).